Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $833000.0.

  • Ligand Pharmaceuticals' Other Non Operating Income rose 10879.99% to $833000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 166.38%. This contributed to the annual value of -$54.9 million for FY2024, which is 312667.45% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Other Non Operating Income is $833000.0, which was up 10879.99% from $1.4 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Other Non Operating Income high stood at $2.9 million for Q4 2023, and its period low was -$41.3 million during Q4 2024.
  • Moreover, its 5-year median value for Other Non Operating Income was -$873000.0 (2023), whereas its average is -$4.8 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 96118.72% in 2021, then crashed by 373997.71% in 2024.
  • Ligand Pharmaceuticals' Other Non Operating Income (Quarter) stood at -$2.1 million in 2021, then skyrocketed by 62.84% to -$793000.0 in 2022, then soared by 461.66% to $2.9 million in 2023, then plummeted by 1540.48% to -$41.3 million in 2024, then skyrocketed by 102.02% to $833000.0 in 2025.
  • Its Other Non Operating Income stands at $833000.0 for Q3 2025, versus $1.4 million for Q2 2025 and -$2.5 million for Q1 2025.